Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonazoid MCE for Ischemic Memory Imaging
NCT03009266Phase 1Unknown
- Sponsor
- Oregon Health & Science University
- Start
- Jul 2018
- Primary completion
- Dec 2019
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of sonazoid in Myocardial ischemia (MI), sponsored by Oregon Health & Science University. Primary endpoints: Dose optimization at 3 months and Detection of Ischemia at 1 year. Status: unknown.
02
Drugs
sonazoid
03
Conditions
Myocardial ischemia (MI)
Beyond the preview
Go deeper on NCT03009266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009266.